Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAPPHIRE: ALT-711 in Isolated Systolic Hypertension
NCT00045981Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Oct 2001
- Primary completion
- May 2003
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of alagebrium in isolated systolic hypertension (ISH), sponsored by Synvista Therapeutics, Inc.. Started Oct 2001; status: completed.
02
Drugs
alagebrium
03
Conditions
isolated systolic hypertension (ISH)
Beyond the preview
Go deeper on NCT00045981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00045981.